GR852606B - - Google Patents

Info

Publication number
GR852606B
GR852606B GR852606A GR850102606A GR852606B GR 852606 B GR852606 B GR 852606B GR 852606 A GR852606 A GR 852606A GR 850102606 A GR850102606 A GR 850102606A GR 852606 B GR852606 B GR 852606B
Authority
GR
Greece
Prior art keywords
nitrogen
hydrogen
methine
alkyl
carbon atoms
Prior art date
Application number
GR852606A
Other languages
English (en)
Inventor
Christopher A Lipinski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of GR852606B publication Critical patent/GR852606B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
GR852606A 1984-10-30 1985-10-29 GR852606B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1984/001767 WO1986002647A1 (en) 1984-10-30 1984-10-30 Spiro-heteroazolones for treatment of diabetes complications

Publications (1)

Publication Number Publication Date
GR852606B true GR852606B (el) 1986-03-04

Family

ID=22182314

Family Applications (1)

Application Number Title Priority Date Filing Date
GR852606A GR852606B (el) 1984-10-30 1985-10-29

Country Status (17)

Country Link
EP (1) EP0180421B1 (el)
JP (1) JPS61109789A (el)
KR (1) KR870000625B1 (el)
AT (1) ATE66228T1 (el)
AU (1) AU553839B2 (el)
DE (1) DE3583791D1 (el)
DK (1) DK166150C (el)
ES (1) ES8704168A1 (el)
FI (1) FI83322C (el)
GR (1) GR852606B (el)
HU (1) HU198051B (el)
IE (1) IE58287B1 (el)
IL (1) IL76855A0 (el)
PH (1) PH23491A (el)
PL (2) PL152323B1 (el)
PT (1) PT81382B (el)
WO (1) WO1986002647A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US5006657A (en) * 1988-07-27 1991-04-09 Pfizer Inc. Intermediates in a resolution process for racemic spiro hydantoins
US4952694A (en) * 1988-07-27 1990-08-28 Pfizer Inc. Novel resolution process for racemic spiro-hydantoins
US5037831A (en) * 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2449030A1 (de) * 1974-10-11 1976-05-20 Schering Ag Neue pyridin-derivate
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4147795A (en) * 1977-02-11 1979-04-03 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4283409A (en) * 1979-10-29 1981-08-11 Pfizer Inc. Imidazolone derivatives

Also Published As

Publication number Publication date
DK495285D0 (da) 1985-10-29
HUT40659A (en) 1987-01-28
KR870000625B1 (ko) 1987-03-26
FI862634A (fi) 1986-06-19
KR860003262A (ko) 1986-05-21
PH23491A (en) 1989-08-16
FI83322B (fi) 1991-03-15
PL152316B1 (en) 1990-12-31
AU4916485A (en) 1986-05-08
ES8704168A1 (es) 1987-03-16
FI83322C (fi) 1991-06-25
IE58287B1 (en) 1993-08-25
AU553839B2 (en) 1986-07-31
DK495285A (da) 1986-05-01
IL76855A0 (en) 1986-02-28
HU198051B (en) 1989-07-28
ES548271A0 (es) 1987-03-16
DE3583791D1 (de) 1991-09-19
EP0180421A1 (en) 1986-05-07
DK166150C (da) 1993-08-09
PT81382B (pt) 1987-11-30
IE852695L (en) 1986-04-30
PL255978A1 (en) 1987-07-13
FI862634A0 (fi) 1986-06-19
JPS61109789A (ja) 1986-05-28
EP0180421B1 (en) 1991-08-14
PL152323B1 (en) 1990-12-31
ATE66228T1 (de) 1991-08-15
DK166150B (da) 1993-03-15
WO1986002647A1 (en) 1986-05-09
PT81382A (en) 1985-11-01

Similar Documents

Publication Publication Date Title
IL89475A0 (en) Biocidal composition comprising imidazole compounds
HK1012341A1 (en) Pyrrolocarbazole
ZA887978B (en) N-phenylalkylbenzamide fungicides
AU553839B2 (en) Spiro - heteroazolones
ES8606295A1 (es) Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas.
ZA927307B (en) Method for treating hypertension
AU6101890A (en) Therapeutic agents for the treatment of peptic ulcer disease
GR3015002T3 (en) 1,4-Dihydro-4-oxo-3-quinolone derivatives as selectively toxic mammalian antibacterial agents.
DE3768449D1 (en) 4-hydroxy-4-(substituierte alkenyl)-cyclohexancarbonsaeure.
ES8504763A1 (es) Procedimiento para preparar 4-(sustituida alquil)-n-(1,3-ditiolan-2-ilideno)anilina.